PDL BIOPHARMA, INC. PDLI Cash Flow

Pdl biopharma, inc. (PDLI)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10
Cash flows from operating activities
Noncash or Part Noncash Acquisition, Other Assets Acquired
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
-109,319	-70,691	416	43,938	-63,844	-68,859	-62,802	-67,626	105,109	110,701	78,085	71,257	14,966	63,659	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: (Loss) income from discontinued operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	328,265	282,255	283,942	264,530	252,846	245,196	224,956	211,669	201,203	198,544	195,028	199,389	135,987	130,260	110,412	91,874	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of convertible notes conversion option and debt issuance costs
5,594	7,237	7,640	7,574	7,400	7,609	8,588	9,555	10,495	11,038	12,137	11,384	10,223	10,009	9,286	9,772	11,358	12,963	14,967	16,338	17,945	18,696	16,872	16,336	14,886	13,320	11,895	11,812	12,064	12,481	0	0	0	-	-	-	-	1,682	0	0	0
Accreted interest on convertible note principal
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of intangible assets
6,284	6,300	0	0	0	-	-	-	-	-	-	-	18,015	12,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of right-of-use assets
918	886	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of Acquisition Costs
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of acquired royalty rights
-	-	-	-	-	-85,256	-96,220	-89,389	-160,272	-162,327	-160,292	-141,024	-56,444	-16,196	-37,197	-16,832	-29,903	-68,367	8,767	-23,115	-44,582	-44,927	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of equity affiliate
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss)
-	-	-	-	-	33	94	-111	-78	-49	-60	-23	-477	-906	110	238	656	985	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
-	-	-	-	-	-41,631	-25,433	-25,035	-1,693	349	-2,450	-1,067	-2,274	-3,716	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of non-recourse notes offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,238	0	0	0
Other amortization and depreciation
2,583	2,901	2,930	3,317	3,519	3,696	3,949	3,803	3,304	2,366	1,480	596	75	18	27	33	39	40	39	-20	-79	-134	-188	-284	-499	-404	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Other amortization and depreciation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Gain (Loss) on Extinguishment of Debt
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6,143	-6,143	-6,143	-6,143	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Discounts and deferred issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Other amortization, depreciation and accretion of embedded derivative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-
Hedge ineffectiveness on foreign exchange contracts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	7	9	10	11	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) on Sale of Investments
-	-	-	-	-	764	764	779	828	108	109	94	790	882	1,298	1,878	1,133	997	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Loss on disposal of property and equipment
-1,500	-1,200	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory Write-down
-	-	-	-	-	-	-	-	2,002	2,000	372	503	454	342	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for bad debts
0	-	0	0	0	-	0	0	64	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hedge ineffectiveness on foreign exchange contracts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Stock-based compensation expense
23,773	7,119	5,347	5,884	4,916	4,758	4,938	3,281	2,983	3,138	4,107	4,218	4,068	3,742	3,346	2,917	2,330	2,045	1,823	1,612	1,808	1,501	1,339	1,115	910	872	821	874	889	937	806	816	541	387	0	0	0	-	-	-	-
Deferred income taxes
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax benefit (expense) from stock-based compensation arrangements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,818	0	0	0
Net excess tax benefit from stock-based compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12,924	0	0	0
Deferred taxes
-	-	-	-	-	13,846	6,917	-1,327	24,645	39,172	24,307	26,032	12,860	-10,676	2,095	1,408	5,693	17,251	-4,206	-8,920	-15,487	-19,842	-6,829	-3,015	-1,735	-999	4,152	6,247	9,101	11,338	12,623	16,337	33,176	31,217	0	0	0	-	-	-	-
Changes in assets and liabilities:
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Accounts receivable
-5,478	-8,195	-2,412	-1,186	-2,255	-9,349	-2,195	-7,659	-7,133	-11,008	-16,480	19,062	21,679	34,120	26,035	-100	300	0	50	-952	-11,650	0	-650	1,352	11,500	-66	900	0	150	-234	0	0	-150	131	-250	-1,950	-1,800	-581	0	0	0
Increase (Decrease) in Accounts and Other Receivables
-	-	-	-	-	-	-	-	-	-	-	-2,881	0	6,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid and other current assets
11,250	-4,464	-2,747	-3,438	4,509	5,025	9,491	13,216	6,495	9,100	5,222	3,730	3,169	1,526	-3,922	-157	-5,924	42	4,267	328	5,114	-2,126	952	-990	-1,710	-387	-3,265	191	-3,286	-5,233	-3,186	826	8,064	199	2,497	-14,107	-10,493	-1,445	0	0	0
Accrued interest on notes receivable
-	-	-	-	-	0	332	13,938	-1,476	-1,475	-1,558	-14,776	888	2,764	1,915	1,996	1,603	2,246	1,509	-838	6,110	6,800	11,324	14,356	10,324	9,530	9,405	8,171	5,322	2,832	0	0	0	-	-	-	-	-	-	-	-
Inventory
25,035	21,923	8,824	1,817	5,377	9,508	294	3,119	3,266	-892	3,919	5,050	3,988	3,227	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
329	156	-43	113	227	2,120	3,552	2,939	3,136	1,400	440	780	-1,698	757	870	857	3,315	865	-1	11	52	63	-207	700	-264	-264	-1,174	-2,085	-2,271	17	1,160	2,047	8,870	6,639	6,602	5,483	-172	-182	0	0	0
Accounts payable
6,810	4,191	4,245	3,707	3,233	-6,642	-1,329	1,168	-10,032	10,840	1,276	6,935	17,285	6,621	6,713	372	47	76	-658	360	205	31	-390	226	-94	-787	656	-40	33	546	928	31	185	-2,012	0	0	0	-	-	-	-
Accrued legal settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	27,500	27,500	0	65,000	0	0	0
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Accrued liabilities
-10,149	-9,341	-8,711	-10,346	-653	-7,449	-14,547	-4,181	1,950	13,120	30,940	24,525	28,842	22,729	10,582	2,800	-1,136	-1,048	157	-185	580	4,343	576	3,269	1,904	-1,447	-664	-1,326	-1,592	62	0	0	0	-	-	-22,404	-26,075	-26,229	0	0	0
Increase (Decrease) in Deferred Revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Increase (Decrease) in Income Taxes Payable
-	-	-	-	-	-1,361	-7,064	-14,783	-8,437	-3,346	1,363	5,209	-11,709	1,352	5,793	9,793	21,019	79	-6,494	-10,817	-5,335	3,293	3,263	-7,936	5,335	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
5,152	4,808	-1,249	-961	-897	-462	-998	9,294	10,059	-1,223	-1,229	-9,576	-9,432	3,800	8,473	9,750	11,748	12,937	5,419	5,288	6,731	5,705	14,186	10,269	191	-2,131	-5,766	-5,306	376	-1,533	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities - continuing operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by operating activities - discontinued operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by operating activities
-	-	-	-	-	-13,425	-28,798	-40,744	-18,679	40,624	73,716	68,578	54,994	101,718	156,144	240,317	322,125	301,465	300,428	302,028	295,986	292,281	284,449	253,189	285,031	269,745	262,419	252,422	247,465	212,506	203,768	204,652	200,830	169,782	154,623	395,850	144,212	184,300	0	0	0
Cash flows from investing activities
Purchases of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29,898	29,039	22,378	32,424	74,744	0	0	0	-	-	-	-
Payments to Acquire Investments
-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Maturities of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	43,780	56,130	47,236	49,236	50,831	48,349	44,550	46,815	50,696	0	0	0	-	-	-	-
Proceeds from Sale of Available-for-sale Securities, Equity
-	-	-	-	-	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments for (Proceeds from) Productive Assets
-	-	-	-	-	-77,969	-89,898	-97,184	-112,382	-107,253	-99,746	-88,735	-68,855	-72,582	-81,677	-73,225	-59,690	-43,407	-29,713	-55,100	-79,760	-102,460	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Sale of Productive Assets
-	-	-	-	-	-	-	-	-	108,169	108,169	108,169	108,169	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of notes receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	9,010	34,259	35,009	40,235	35,235	23,976	20,226	180,000	230,000	315,000	336,404	196,129	148,708	98,034	117,469	92,744	97,590	0	0	0	-	-	-	-	-	-	-	-
Repayment of notes receivable
-	-	-	-	-	-	-	-	-	8,190	-46,511	8,142	7,890	0	0	0	0	-	-	-	-	-	-	-	-	59,279	64,279	21,779	14,279	5,000	0	0	0	-	-	-	-	-	-	-	-
Purchase of property and equipment
814	763	386	771	3,167	4,523	4,778	4,507	2,161	1,297	1,185	730	559	25	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	51	0	0	0	-	-	-	-	-	-	-	-
Net cash used in investing activities - continuing operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities - discontinued operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Maturities of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Net cash provided by/(used in) investing activities
-	-	-	-	-	56,704	71,345	324,228	351,168	458,887	436,406	184,691	-27,945	-144,510	-143,207	-232,861	-68,092	-79,648	-82,568	39,844	-110,809	-138,109	-488,464	-477,431	-342,307	-296,840	8,559	-78,768	-53,177	-71,708	-28,972	14,778	6,958	-24,048	-42,637	-56,757	-67,328	-36,896	0	0	0
Cash flows from financing activities
Cash payment for repurchase of convertible notes
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of Secured Debt
-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	93,370	115,268	118,962	114,428	110,900	0	0	0	-	-	-	-
Net receipts for capped call transactions
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments for Repurchase of Convertible Preferred Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	220,397	203,672	203,672	48,622	56,191	29,906	29,906	29,906	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100,000	100,000	100,000	100,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of Notes Payable
-	-	-	-	-	-	-	-	-	-	-	-	-	0	50,000	75,000	100,000	75,000	68,750	62,500	56,250	75,000	56,250	37,500	18,750	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	607	1,145	608	608	9,825	9,287	9,824	9,824	0	0	0	0	845	0	0	0	-	-	-	-	-	-	-	-
Net proceeds from the issuance of convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	300,000	300,000	300,000	300,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net receipts for capped call transactions
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of contingent consideration
0	1,071	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of Company common stock
61,836	86,898	100,000	96,771	89,837	49,109	25,000	23,604	25,913	30,000	30,000	30,000	7,647	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of purchased call options, net of tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,427	11,427	11,427	11,427	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of non-recourse notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Payments of Dividends
-	-	-	-	-	-	-	-	-	222	171	171	8,371	16,583	41,117	65,657	81,991	98,307	98,045	97,552	97,064	96,557	93,198	90,130	87,068	84,006	83,999	83,982	83,960	83,942	83,838	83,828	83,824	83,828	133,055	231,831	150,924	130,043	0	0	0
Net settlement of stock-based compensation awards
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,924	0	0	0
Net cash used in financing activities - continuing operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities - discontinued operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities
-	-	-	-	-	-175,955	-151,648	-237,259	-241,738	-119,399	-106,627	-19,695	-3,372	-28,937	-134,202	-183,667	-380,051	-294,311	-271,612	-264,332	-102,544	42,903	166,026	187,294	209,119	-9,815	-83,972	-106,687	-153,464	-178,130	-199,338	-202,946	-193,133	-188,764	-155,340	-135,129	-269,845	-239,057	0	0	0
Net increase/(decrease) in cash and cash equivalents
-	-	-	-	-	-132,676	-109,101	46,225	90,751	380,112	403,495	233,574	23,677	-71,729	-121,265	-176,211	-126,018	-72,494	-53,752	77,540	82,633	197,075	-37,989	-36,948	151,843	-36,910	187,006	66,967	40,824	-37,332	-24,542	16,484	14,655	-43,030	-43,354	-43,290	-192,961	-91,653	0	0	0
Supplemental cash flow information
Cash (refunded) paid for income taxes
58	-2,689	-2,899	-2,868	388	3,805	12,265	33,141	43,890	43,366	35,120	30,205	28,120	50,000	93,000	118,000	138,000	168,000	180,000	192,000	207,000	189,000	172,000	165,000	145,000	139,000	124,000	124,000	109,000	99,000	93,000	85,000	87,000	83,000	0	0	0	-	-	-	-
Line of Credit Facility, Commitment Fee Amount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Expenditures Incurred but Not yet Paid
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosures of non-cash financing activities
Assets held for sale reclassified from other assets to intangibles
-	-	-	-	-	1,811	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	0	9,286	-	8,704	11,104	8,938	11,410	10,872	12,333	15,656	16,987	19,267	19,418	19,317	18,439	18,128	14,175	13,863	10,997	10,997	11,579	13,362	15,754	18,466	21,514	22,536	25,627	0	0	0	-	-	-	-
Other Significant Noncash Transaction, Value of Consideration Given
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,794	24,082	24,082	24,082	171,879	157,591	157,591	157,591	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Assets held for sale reclassified from notes receivable to other assets
-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-